Tempus has launched a suite of new testing solutions to help doctors identify patients with HER2- or FOLR1-expressing tumors, potentially making them suitable candidates for specific medicines, such as antibody-drug conjugates.

The new solutions focus on testing for HER2 and FOLR1 through immunohistochemistry (IHC). Alongside this, Temps offers next-generation sequencing assays, and these new tests are available to supplement those assays. Moreover, these tests are now available for all solid tumor cancers. HER2 and FOLR1 tests are recommended for several types of cancer. 

According to Tempus, these new diagnostic tools will provide physicians with the means to identify which therapies could be most beneficial for their patients. By identifying the presence of markers like HER2, it is believed that these tests can provide insights into the effectiveness of certain treatments and can potentially enhance a patient’s treatment outcome.